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Since Richard Feynman and his famous talk “There’s plenty of room at the bottom” in an American
Physical Society meeting at Caltech in 1959, Nanotechnology has led to the development of novel
materials and devices with a wide-range of applications, especially in imaging, diagnostics, and
therapy, which contributed to the early detection and treatment of cancer and metastasis (Ferrari,
2005; Conde et al., 2012a; Schroeder et al., 2012).
Although Nanotechnology is thought to be a new branch of Science that has only emerged
over the past decade, nanoparticles (for example, gold nanoparticles) have been used, even though
inadvertently, for several thousand years (Salata, 2004). In fact, these nanoparticles have been
regarded as precious for as long as humans have existed, and have been associated from the time
of gods and kings to the time of Faraday (Wagner et al., 2000; Edwards and Thomas, 2007).
Today, nanotechnology is a flourishing field that is helping to address critical global problems
from cancer treatment to climate change. In fact, nanotechnology is everywhere and is everyday
practice.
Nowadays, nanomaterials and nanoparticles have gained increasing interest due to their extraor-
dinary electrical, optical, and chemical properties, high stability and biological compatibility,
controllable morphology and size dispersion, and easy surface functionalization (Anker et al., 2008;
Parveen et al., 2012; Conde et al., 2014a).
A unique feature of nanomaterials in the nanometer range (such as high surface-to-volume ratio
or size-dependent optical properties) is that they are radically different from those of their bulk
materials and with a huge potential to be used in the clinical field for disease diagnostics and
therapeutics (Kim, 2007; Heath and Davis, 2008). The most common bioapplications in which
nanomaterials and nanoparticles have been used so far are labeling, delivering, heating, sensing, and
detection (Sperling et al., 2008), using several approaches, such as gene delivery, tumor targeting, or
drug delivery, especially in cancer (Figure 1).
Cancer is the one of first leading causes of mortality worldwide, with more than 14 million new
cases and 8.2 million cancer-related deaths only in 2012. According to the National Cancer Institute,
in 2015, an estimated 1.5 million new cancer cases will be diagnosed and almost 600,000 cancer
deaths will occur only in the United States (Siegel et al., 2014). The three most common cancers
in 2015 are projected to be breast cancer, lung and bronchus cancer, and prostate cancer. And the
problem is far away from getting better. The global cancer rates could increase by 50% to 15 million
by 2020, according to a report from theWorldHealthOrganization. And the national costs for cancer
care in the United States totaled nearly $125 billion in 2010 and could reach $156 billion in 2020.
Although we have assisted in the last 50 years to rapid technological advances, the full under-
standing of the molecular onset of this disease is still far from being achieved, as well as the search
for new mechanisms of treatment that rely on selectivity and specificity toward cancer cells only
(Peer et al., 2007). It is here that nanotechnology enters the fight offering a prosperity of utensils for
cancer diagnostics and therapy. The main challenge is to develop a system capable of circulating in
the blood stream undetected by the immune system or being applied locally for sustained release
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What Nano can do beyond 
discovering materials? 
What have we learned
so far? 
Which new tools lead to new 
Nanoscience? 
Where are the commercial
products on Nanotechnology? 
Why Nano is not translating into clinics? 
FIGURE 1 | The golden age in cancer nanobiotechnology: promises
and pitfalls. After a decade of substantial investment around the world, we
are often asked what nano can do beyond discovering new systems and
methods to produce novel materials? Although all studies described so far
provide a baseline level of data in support of the effectiveness and safety of
nanomaterials, we wonder what have we learned so far? Which new tools
lead to new Nanoscience? Where are the commercial products on
Nanotechnology? Is nanotechnology truly the next trillion-dollar market?
of therapeutic payloads, able to identify the required target and
signal it for efficient and specific delivery (Conde et al., 2014b).
As a result, nanotechnology is playing a pivotal role in providing
new types of nanotherapeutics for cancer that have the potential
to provide highly active and specific therapies with minimal side
effects andmaximum therapeutic outcome. Smart andmultifunc-
tional nanomaterials are one of those nanosystems that represent
non-toxic and multipurpose mediators for a variety of biomedical
applications, such as diagnostic and imaging assays (Cao et al.,
2005; Conde et al., 2010; Kim et al., 2011), phototherapy and
radiotherapy improvement (Hainfeld et al., 2008; Oh et al., 2014),
as well as tumor targeting (Conde et al., 2012b, 2013, 2014c), gene
silencing (Conde et al., 2012b, 2015a,b; Jiang et al., 2013), and
drug delivery (Gibson et al., 2007; Han et al., 2007; Lai et al., 2007;
Conde et al., 2015b).
This is feeding the biopharmaceutical companies to develop
and expand the pool of potential therapeutic targets. The growth
of this target pool will help overcome the already precarious bot-
tlenecks in drug discovery pipelines, as the key steps for validat-
ing targets as legitimate candidates for therapeutic intervention.
Nanotechnologywill undoubtedly be crucial for identifying useful
drug target candidates and for validating their importance and
efficacy in disease states, such as cancer (Conde et al., 2015a).
Actually, cancer nanotechnology may offer new opportunities for
personalized oncology in which diagnostics and therapy are based
on each individual’s molecular and cellular profile (Ferrari, 2005).
In the last 30 years, thousands and thousands of nanosystems
were published in peer-review journals. These systems will most
likely modernize our understanding of biological mechanisms
and push forward the translation to clinical practice. However,
after three decades of substantial investment around the world,
we are often asked what Nano can do beyond discovering new
systems and methods to produce innovative materials? Although
all studies described so far provide an important baseline level of
data in support of the effectiveness and safety of nanomaterials, we
wonder what have we learned so far?Which new tools lead to new
nanoscience?Where are the commercial products of nanotechnol-
ogy? Is nanotechnology truly the next trillion-dollar market?
At the first place, it is imperative to learn how advances in
nanosystem’s aptitudes are being used to find new diagnostic and
therapy platforms driving the expansion of personalizedmedicine
in oncology. And most important to learn what approaches are
proving fruitful results in turning promising clinical data into
treatment realities (Conde et al., 2014b).
A recurrent problem that we can find in literature is that the
majority of studies on nanomaterials do not consider the final
application to guide the design of nanomaterials. Instead, the
focus is predominantly on engineering materials with specific
physical or chemical properties (Albanese et al., 2012). Besides,
we are still considering numerous studies reporting in vitro cell
studies only. Despite the significant efforts toward the use of nano-
materials in biologically relevant research, more in vivo studies are
needed to assess the applicability of these materials as delivery
agents. Future in vivo work will need to carefully consider the
correct choice of chemical modifications to incorporate into the
multifunctional nanocarriers to avoid activation of off-target and
side effects, as well as toxicity. Although is true that clinical trials
using nanomedicines are not very common, most researchers do
not seem to take benefit of the published studies in clinical trials
to guide the design of new materials. Published trials with patient
data can guide and focus researchers in their study goals, as well
as to achieve and improve long-term positive consequences for
the growth and expansion of the nanotechnology field. Therefore,
it is extremely encouraging for academia and industry to pub-
lish nanotechnology-based clinical trials in nanotechnology and
materials journals, even the ones with negative results. These data
would serve as a foundation for measuring real clinical value and
to develop stronger and reliable protocols in future clinical trials.
In the absence of a future proactive intervention, we take the
risk that nanomedicine studies founded on limited clinical trans-
lation may discourage not only public confidence but also more
importantly drive funding to other fields of research, which are
supposed to engender more valuable results.
So why the majority of the manuscripts published in top nan-
otechnology journals with new nanomaterials do not report on
clinical data to validate their findings? Although we know that
maintaining animal set-ups is expensive and time consuming and
that sponsoring clinical trialsmay costmillions of dollars, a greater
problem may also rely on the genesis of most researchers training
skills. Most of the nanotechnology research teams are trained
in physics, chemistry, and/or engineering and lack the bridge
between technology and clinics. And the opposite also occurs
clinicians classically do not tend to endeavor into nanotechnology
research. This may explain the disproportional level between
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nanomaterials production and their translation into clinics.Only a
very small portion of all nanomaterials were produced to improve
a bench-to-bedside approach to translational research. Outcomes
like this must be followed by extensive laboratory work, which
results in improved screening procedures and a new therapy of
great potential, although the final product should always be part
of a two-way interaction between laboratory scientists and clini-
cians. With chemists, biologists, and materials scientists working
together with clinicians and engineers, but especially with “trans-
lational entrepreneurs” new solutions to crucial nanobiomedical
problems will hopefully be found (Conde et al., 2014b).
Another important question is that after billions of dollars
of investments in nanoscience and nanotechnology around the
world we are often asked: where are the commercial products on
nanotechnology? and is nanotechnology the next trillion-dollar
market?
In fact, the National Science Foundation estimates that the
global nanotechnology market could be valued in $1 trillion by
2015, and expected to be a fundamental driver of job creation in
the years and decades ahead. This occurs once nanotechnology is
now entering sectors as diverse as healthcare, automanufacturing,
and food production. A key driver of market development is
the “acceptance” and “adoption” of nanotechnology by the main
industries.
However, these numbers are more reminiscent of supermarket
tabloids than serious market research, once many of the innova-
tive and disruptive technologies have failed to emerge. Certainly,
7 years from the beginning of theNational Nanotechnology Initia-
tive, there appears to be a diminutive sign of a nanotechnology-
based industry, although important amounts of R&D are being
assumed by several industries. We are in danger of letting the
commercialization of nanotechonology at the hand of speculative
and science fiction tabloids (Weiss, 2015). In fact, developing com-
mercial products may take several years and millions of dollars in
order to progress and overcome the “Valley of Death,” which usu-
ally overlaps with the phase when the company receives an initial
capital contribution to begin generating revenues. Since during
this phase, the additional financing is scarce, the company may
become vulnerable to cash flow requirements. The only way to
overcome this period is to have a “champion product that carries
the trophy,” bridging the “Valley of Death.” A successful outcome
usually requires a strategy based on the knowledge of potential
resources, leadership in attaining the resources and passionate
dedication of staff to executing the development plan.
Above and beyond, numerous “barricades” stand between ver-
ification of efficacy and safety, ethical issues, as well as regulatory
approval by the Food and Drug Administration (FDA), making
it extremely difficult to advance to commercialization, and make
it to and through clinical trials and patients at the end. In fact,
the turnover of the “commercialization” or the proof of concept
occurs only after spending huge amounts of money and time. If a
specific product is able to go through the “Valley of Death” with
success the probability for reaching the market is higher. But this
process may take as long as 20 years (Conde and Artzi, 2015).
Usually in the first year, we may have ~10,000 leading discoveries
that will drop down into ~250 after safety and efficacy testing in
animals in the following 2–4 years. Between year 6 and 10 this
number decreases to ~10 after human clinical trials and to 1 at the
end of 15 years following regulatory approval. To further hamper
this process, after regulatory approval, ~70% of the products need
additional studies.
For nanotechnology developments to range their full potential,
the FDAmust play a progressively vital role as an agency dedicated
not only guaranteeing safe and active products but also to encour-
age and contribute more aggressively in the scientific and techno-
logical research initiative directed toward new nanotechnology-
based platforms. In fact, more than 30% of the newmedical prod-
ucts recently approved by the FDA are combination of products
previously approved. Intense debates about the safety of nanoscale
science are likely to endure for many years until a sufficiently
strong foundation of applications in the field exists on which to
base long-term decisions. For this reason, we have and must to
modernize our evaluation and approval processes to guarantee
that ground-breaking products reach the patients who need them,
when they need them.
We know that test protocols must run according to estab-
lished standards for drugs, as well as for device biomaterials,
components, and finished products. However, since living tissues
behave differently betweennano andmacro structures, unique test
protocols must be developed. Possibly, expenditures experienced
in qualifying new, potentially “disruptive” nanotechnology-based
medical products may exceed those of conventional products.
In summary, the major recommendations to the field pass
intensively trough the increase in support the commercialization
of nano products, including nano manufacturing, ensuring not
only the support of translation science as well as medicine and
engineering but also a better coordination between the involved
agencies (Weiss, 2010).
Increased efforts in nanoscience tutoring and in understanding
the social impacts of nanotechnology are also of utmost impor-
tance. In fact, one of the first challenges may be to raise con-
sciousness and instruct the community on nanotechnology and
its potential impact.
Another key reference is the fact that novel nanoscale tools
enable insight and awareness, smart answers, and original ques-
tions, leading to a biotechnology revolution, raising our efforts in
nanoscience and nanotechnology.
Last but not least, it is essential that governments, Institu-
tions, and Funding Agencies support selected fields of science
and technology based on the acknowledgment of the possible
reimbursements or advances for society, in order to accelerate the
development of the field.
An active approach, which consciously support research at
interfaces between materials and medicine (i.e., nanomedicine),
will require systemic changes, as well as new fundingmechanisms.
National or international funding agencies should foster changes
in the R&D support systems, by realizing the pioneering potential
of such an interdisciplinary field as nanotechnology. Moreover,
to monitor the previously recognized trends and gradually adjust
them as a request that the R&D community imposes may be the
key of a reliable, sustained, and golden age of nanobiotechnology.
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